BioNTech SE American Depositary Share (BNTX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
BioNTech SE American Depositary Share (BNTX) advanced +1.30% to $89.13 as options desks priced 60% call premium vs. 40% put protection around the $87 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
BioNTech (NasdaqGS:BNTX) and DualityBio reported positive topline results from the DYNASTY-Breast02 Phase 3 trial in HR+/HER2-low metastatic breast cancer, including a statistically significant improvement in progression
Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real question is whether Wall Street is pricing in a cancer breakthrough that has yet to prove itself outsi
Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
Tempus AI heads into its Nov. 2 earnings report with a $1.5 billion acquisition pending and shares down more than 20% in a month, putting serious pressure on the core business to prove it can carry the weight.
Moderna's personalized melanoma vaccine cleared its primary hurdle in a late-stage trial, yet shares are sinking fast. The gap between what the data promised and what it delivered is forcing traders to rethink how much t
BioNTech and DualityBio report modest Phase 3 breast cancer survival gains alongside higher lung toxicity, limiting overall patient benefit.
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3
BioNTech (NasdaqGS:BNTX) just expanded its oncology pipeline by announcing new Phase 2 data for pumitamig plus docetaxel in metastatic non small cell lung cancer, alongside a new Phase 3 collaboration in triple negative
BioNTech (NasdaqGS:BNTX) and Gilead Sciences agreed to a clinical trial collaboration to study pumitamig with sacituzumab govitecan in first-line metastatic triple-negative breast cancer. The partners plan to adapt an ex
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +14.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BNTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BNTX. Explore sector supply chains on /butterfly.
Why BNTX Stock advanced +1.30% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.